1
|
Catani JPP, Medrano RFV, Hunger A, Del Valle P, Adjemian S, Zanatta DB, Kroemer G, Costanzi-Strauss E, Strauss BE. Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. Transl Oncol 2016; 9:565-574. [PMID: 27916291 PMCID: PMC5143354 DOI: 10.1016/j.tranon.2016.09.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 09/29/2016] [Accepted: 09/29/2016] [Indexed: 02/06/2023] Open
Abstract
Therapeutic strategies that act by eliciting and enhancing antitumor immunity have been clinically validated as an effective treatment modality but may benefit from the induction of both cell death and immune activation as primary stimuli. Using our AdRGD-PG adenovector platform, we show here for the first time that in situ gene transfer of p19Arf and interferon-β (IFNβ) in the LLC1 mouse model of lung carcinoma acts as an immunotherapy. Although p19Arf is sufficient to induce cell death, only its pairing with IFNβ significantly induced markers of immunogenic cell death. In situ gene therapy with IFNβ, either alone or in combination with p19Arf, could retard tumor progression, but only the combined treatment was associated with a protective immune response. Specifically in the case of combined intratumoral gene transfer, we identified 167 differentially expressed genes when using microarray to evaluate tumors that were treated in vivo and confirmed the activation of CCL3, CXCL3, IL1α, IL1β, CD274, and OSM, involved in immune response and chemotaxis. Histologic evaluation revealed significant tumor infiltration by neutrophils, whereas functional depletion of granulocytes ablated the antitumor effect of our approach. The association of in situ gene therapy with cisplatin resulted in synergistic elimination of tumor progression. In all, in situ gene transfer with p19Arf and IFNβ acts as an immunotherapy involving recruitment of neutrophils, a desirable but previously untested outcome, and this approach may be allied with chemotherapy, thus providing significant antitumor activity and warranting further development for the treatment of lung carcinoma.
Collapse
Affiliation(s)
- João Paulo Portela Catani
- Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of Sao Paulo/LIM 24, University of São Paulo School of Medicine, Brazil
| | - Ruan F V Medrano
- Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of Sao Paulo/LIM 24, University of São Paulo School of Medicine, Brazil
| | - Aline Hunger
- Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of Sao Paulo/LIM 24, University of São Paulo School of Medicine, Brazil
| | - Paulo Del Valle
- Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of Sao Paulo/LIM 24, University of São Paulo School of Medicine, Brazil
| | - Sandy Adjemian
- Laboratory of Cell and Molecular Biology, Department of Immunology, Biomedical Sciences Institute, University of São Paulo, Brazil
| | - Daniela Bertolini Zanatta
- Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of Sao Paulo/LIM 24, University of São Paulo School of Medicine, Brazil
| | - Guido Kroemer
- Equipe 11 Labellisée Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; U1138, INSERM, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
| | - Eugenia Costanzi-Strauss
- Gene Therapy Laboratory, Department of Cell and Developmental Biology, Biomedical Sciences Institute, University of São Paulo, Brazil
| | - Bryan E Strauss
- Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of Sao Paulo/LIM 24, University of São Paulo School of Medicine, Brazil.
| |
Collapse
|
2
|
Liu F, Du J, Xian J, Liu Y, Liu S, Lin Y. Improved therapeutic effectiveness by combining recombinant p14(ARF) with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma. Am J Otolaryngol 2015; 36:763-71. [PMID: 26545468 DOI: 10.1016/j.amjoto.2015.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/15/2015] [Accepted: 07/31/2015] [Indexed: 02/05/2023]
Abstract
PURPOSE The tumor suppressor p14(ARF) and proto-oncogene epidermal growth factor receptor (EGFR) play important roles in the development of laryngeal squamous cell carcinoma (LSCC). This study was aimed to determine whether combining recombinant p14(ARF) with antisense complementary DNA of EGFR could improve the therapeutic effectiveness in LSCC. MATERIALS AND METHODS After human larynx cancer cells (Hep-2) were infected with recombinant adenoviruses (Ad-p14(ARF) and Ad-antisense EGFR) together or alone in vitro, the proliferation and cell cycle distribution of Hep-2 cells were detected by MTT assay and flow cytometer analysis, respectively. Furthermore, the antitumor effects of recombinant adenoviruses together or alone on Hep-2 xenografts were examined in vivo. The levels of p14(ARF) and EGFR expressed in Hep-2 cells and xenografts were determined by western blot assay. RESULTS Ad-p14(ARF) combining with Ad-antisense EGFR markedly inhibited the Hep-2 proliferation compared with alone (P=0.001, P=0.002 respectively). Combination of Ad-p14(ARF) and Ad-antisense EGFR led to the proportion of Hep-2 cells in G0/G1 phases increased by up to 86.9%. The down-expression of EGFR protein and overexpression of p14(ARF) protein were observed in vitro and in vivo, and this effect was preserved when Ad-p14(ARF) was combined with Ad-antisense EGFR. Besides, Ad-p14(ARF) plus Ad-antisense EGFR significantly (P<0.05) increased the antitumor activity against Hep-2 tumor xenografts comparing with Ad-p14(ARF) or Ad-antisense EGFR alone. CONCLUSION Combination Ad-p14(ARF) with Ad-antisense EGFR significantly increased the antitumor responses in LSCC. An effectively potential gene therapy to prevent proliferation of LSCC was provided.
Collapse
Affiliation(s)
- Feng Liu
- West China School of Medicine, West China Hospital, Sichuan University Department of Otorhinolaryngology, Chengdu, People's Republic of China
| | - JinTao Du
- West China School of Medicine, West China Hospital, Sichuan University Department of Otorhinolaryngology, Chengdu, People's Republic of China
| | - Junming Xian
- West China School of Medicine, West China Hospital, Sichuan University Department of Otorhinolaryngology, State Key Laboratory of Biotherapy, Chengdu, People's Republic of China.
| | - Yafeng Liu
- West China School of Medicine, West China Hospital, Sichuan University Department of Otorhinolaryngology, Chengdu, People's Republic of China
| | - Shixi Liu
- West China School of Medicine, West China Hospital, Sichuan University Department of Otorhinolaryngology, Chengdu, People's Republic of China
| | - Yan Lin
- Department of Otorhinolaryngology, the First Affiliated Hospital of Kunming Medical College, Kunming, China
| |
Collapse
|
3
|
Liu F, Du J, Xian J, Liu Y, Liu S, Lin Y. WITHDRAWN: Improved therapeutic effectiveness by combining recombinant p14ARF with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma. Am J Otolaryngol 2015:S0196-0709(15)00033-2. [PMID: 26585064 DOI: 10.1016/j.amjoto.2015.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Accepted: 01/19/2015] [Indexed: 02/05/2023]
Abstract
This article has been withdrawn at the request of the author(s) and/or editor. The publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Collapse
Affiliation(s)
- Feng Liu
- Department of Otorhinolaryngology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China
| | - JinTao Du
- Department of Otorhinolaryngology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China
| | - Junming Xian
- Department of Otorhinolaryngology, State Key Laboratory of Biotherapy, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
| | - Yafeng Liu
- Department of Otorhinolaryngology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China
| | - Shixi Liu
- Department of Otorhinolaryngology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China
| | - Yan Lin
- Department of Otorhinolaryngology, the Second Affiliated Hospital of Kunming Medical College, Kunming, 650101, People's Republic of China
| |
Collapse
|
4
|
Mizokami D, Araki K, Tanaka N, Suzuki H, Tomifuji M, Yamashita T, Inoue M, Hasegawa M, Shiotani A. Sendai virus transgene in a novel gene therapy for laryngotracheal disease. Laryngoscope 2013; 123:1717-24. [DOI: 10.1002/lary.23917] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/05/2012] [Indexed: 12/14/2022]
Affiliation(s)
- Daisuke Mizokami
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| | - Koji Araki
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| | - Nobuaki Tanaka
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| | - Hiroshi Suzuki
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| | - Masayuki Tomifuji
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| | - Taku Yamashita
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| | | | | | - Akihiro Shiotani
- Department of Otolaryngology-Head & Neck Surgery; National Defense Medical College; Tokorozawa; Saitama
| |
Collapse
|
5
|
Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma. Cancer Gene Ther 2012; 19:328-35. [PMID: 22388454 DOI: 10.1038/cgt.2012.5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The purpose of this study is to develop a specific and efficient targeted gene therapy candidate approach for laryngeal carcinomas. Several promoters of human squamous cell carcinoma antigen 2(SCCA2), secretory leukocyte protease inhibitor (SLPI) and Survivin genes were cloned from human genomic DNA and evaluated for tumor-specific transcription potential in human laryngeal carcinoma Hep-2 cells by dual luciferase assays. One SLPI promoter fragment (677 bp) showed the highest efficiency and specificity, and was used to control the expression of a recombinant active caspases-3 (revCasp3), which could trigger apoptosis without activation of its upstream cascade elements once expressed in a cell, in an adenoviral vector (Ad-SLPI-revCasp3), and its antitumor efficacy was assessed. In vitro infection with Ad-SLPI-revCasp3 showed revCasp3 could be specifically expressed in Hep-2 cells, resulting in efficient activation of endogenous Caspase-3 and subsequent apoptosis of Hep-2 cells. In Hep-2 nude mice xenograft model, intratumoral administration of Ad-SLPI-revCasp3 significantly inhibited tumor growth without obvious loss of body weight and obvious hepatic toxicity. In summary, our study showed the specific and efficient apoptosis-inducing potential of Ad-SLPI-revCasp3, and this makes it a new candidate approach of targeted gene therapy for laryngeal squamous cell carcinoma, which needs further systematic investigation.
Collapse
|
7
|
High efficient generation of replication-defective adenoviruses containing thymidine kinase by homogeneous recombination in bacteria. Chin Med J (Engl) 2007. [DOI: 10.1097/00029330-200709020-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|